U.K. regulators will reportedly recommend that the National Health Service not cover Eli Lilly’s (NYSE:LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive.

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations. Read the full article Eli Lilly & Co.

LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The weight-loss treatment ...

Lily K. Calcagnini ’18 is a current Editorial writer and previous columns editor living in Dunster House. Originally from New York City, Lily studies History & Literature and Spanish in Cambridge.

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...